Following The Announcement By Asahi Kasei That It Controls Over 90% Of Calliditas Therapeutics Has Resolved To Apply For Delisting Its Common Shares From Nasdaq Stockholm And Its American Depositary Shares From The Nasdaq Global Select Market
Following The Announcement By Asahi Kasei That It Controls Over 90% Of Calliditas Therapeutics Has Resolved To Apply For Delisting Its Common Shares From Nasdaq Stockholm And Its American Depositary Shares From The Nasdaq Global Select Market
随着旭化成宣布控制超过90%的calliditas therapeutics，决定申请将其普通股票从纳斯达克斯德哥尔摩市场退市，并将其美国存托凭证从纳斯达克全球精选市场退市。
Following The Announcement By Asahi Kasei That It Controls Over 90% Of Calliditas Therapeutics Has Resolved To Apply For Delisting Its Common Shares From Nasdaq Stockholm And Its American Depositary Shares From The Nasdaq Global Select Market
随着旭化成宣布控制超过90%的calliditas therapeutics，决定申请将其普通股票从纳斯达克斯德哥尔摩市场退市，并将其美国存托凭证从纳斯达克全球精选市场退市。
资讯热榜
更新时间